Immutep (ASX:IMM) - CEO, Marc Voigt (left)
CEO, Marc Voigt (left)
Source: ShareCafe
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Biotechnology company Immutep (IMM) has released further interim results from its phase two TACTI-002 study in patients with lung, head and neck cancers
  • The study evaluates a combined treatment using Immutep’s lead product candidate efti, along with pembrolizumab
  • So far, results show the combined treatment has therapeutic benefits and a good safety profile, standing it in good stead for further clinical development
  • Immutep will enrol up to 25 extra patients in the study and expects to report more mature trial data in the first half of 2021 
  • Shares have been trading 1.7 per cent lower at 29 cents

Immutep (IMM) has released further interim data from its Phase II TACTI-002 Study in patients with lung, head and neck cancers.

The study evaluates a combined treatment using Immutep’s eftilagimod alpha (efti) with MSD’s KEYTRUDA (also known as pembrolizumab) candidate. 

Efti is a soluble LAG-3 fusion protein and antigen-presenting cell activator, while pembrolizumab is a PD-1 inhibitor. 

The trial is being conducted with Merck & Co (MSD) and is enrolling up to 109 patients with second-line head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) in first and second line.

Interim results show the combined treatment has therapeutic benefits and a good safety profile as Principal Investigator Dr Matthew Krebs explained. 

“In first-line NSCLC and second-line HNSCC we are seeing very encouraging results compared to historical studies where pembrolizumab has been given as monotherapy in comparable patient groups,” he stated.

“These results highlight the potential therapeutic benefit of adding efti to the checkpoint inhibitor pembrolizumab, together with an excellent safety profile. The data strongly support further evaluation of the combination in both lung and head and neck cancers,” he continued. 

Immutep Chief Scientific Officer and Chief Medical Officer Dr Frederic Triebel said the company is very encouraged by the number of patients responding to the treatment, including those who would not typically respond to immune checkpoint therapy.

“The results from this trial, and our other trials, continue to support our hypothesis that the combination of our lead product candidate, efti, with a PD-1 inhibitor such as pembrolizumab, should result in a meaningful benefit to patients across various cancers. These results are supportive of further late-stage clinical development,” he explained.

Immutep will enrol up to 25 extra patients in the study and expects to report more mature trial data in the first half of 2021.

Shares have been trading 1.7 per cent lower at 29 cents at 1:30 pm AEDT.

imm by the numbers
More From The Market Online

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…

TruScreen continues global growth with product registration in Kenya

TruScreen Group has received product registration in the Republic of Kenya, a priority market for cervical…

Artrya expands US commercial momentum with five-year HonorHealth agreement

Atrya has signed a five-year commercial agreement with major Arizona health system HonorHealth and becomes fifth…